Promoting access to biosimilars: a public−private partnership model for biosimilar development in underserved populations
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 2
Abstract
Biologicals represent the future of pharmaceutical treatments and innovation. Yet, emerging and developing markets lack access to these often essential medicines. Biosimilar development represents a potential solution to this problem, by offering lower cost and improved access, but is also associated with patient safety issues. In order to synergize these divergent challenges, targeted public−private partnerships that bring together shared goals and resources of the public sector, global firms, and local manufacturers need to be explored. Crucial to their success will be equitable intellectual property rights management and coordination and collaboration with effective governance and incentives.
Authors and Affiliations
Timothy Ken Mackey, Bryan A Liang
Keywords
Related Articles
- EP ID EP355162
- DOI 10.5639/gabij.2012.0102.018
- Views 145
- Downloads 0
Assessing biosimilarity using the method of generalized pivotal quantities
Introduction: For generic approval of small-molecule (chemical) drug products, US Food and Drug Administration requires evidence of equivalence in average bioavailability from bioavailability and bioequivalence studies....
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act
Four changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act will markedly improve these programmes: expanded attention paid to neonatal studies, support for the off -patent programme,...
Generic clopidogrel–the medicines agency’s perspective
A number of generic products containing clopidogrel as the active substance have been marketed in Austria and the EU for some time. Due to different clopidogrel salt preparations and different indications, doubts arose a...
Suggested evaluation of biological drugs role for WHO – Editor’s response
The Editor-in-Chief expresses his concerns about the proposal of a WHO run system to approve copy biologicals in the Milani and Gaspani paper [1].
Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care
Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care Oncologists have been urged to embrace biosimilar drug substitution to help control the spiralling costs of cancer care. However, t...